| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Other Events
Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva |
| 13 Oct 2026 |
8-K: Other Events
On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) (“Livmarli”) for the treatment of cholestatic pruritus in patients aged 6 months o... |
| 28 Sep 2026 |
8-K: Other Events
On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total ne... |
| 08 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, eff... |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 18 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 18 May 2026 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more |
| 06 May 2026 | 8-K: Results of Operations and Financial Condition |
| 04 May 2026 | 8-K: Other Events |
| 27 Apr 2026 | 8-K: Other Events |
| 25 Feb 2026 | 8-K: Results of Operations and Financial Condition |
| 26 Jan 2026 | 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure +1 more |
| 12 Jan 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 19 Dec 2025 | 8-K: Other Events |
| 19 Dec 2025 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 08 Dec 2025 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more |
| 17 Nov 2025 | 8-K: Other Events |
| 04 Nov 2025 | 8-K: Results of Operations and Financial Condition |
| 06 Aug 2025 | 8-K: Results of Operations and Financial Condition |
| 30 May 2025 | 8-K: Submission of Matters to a Vote of Security Holders |
Loading...
